Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Local activation of coagulation factor XIII reduces systemic complications and improves the survival of mice after Streptococcus pyogenes M1 skin infection.

Deicke C, Chakrakodi B, Pils MC, Dickneite G, Johansson L, Medina E, Loof TG.

Int J Med Microbiol. 2016 Nov;306(7):572-579. doi: 10.1016/j.ijmm.2016.06.001. Epub 2016 Jun 8.

PMID:
27338836
2.

Nonclinical analysis of the safety, pharmacodynamics, and pharmacokinetics of plasma-derived human FXIII concentrate in animals.

Beyerle A, Solomon C, Dickneite G, Herzog E.

Pharmacol Res Perspect. 2016 Mar 10;4(2):e00227. doi: 10.1002/prp2.227. eCollection 2016 Apr.

3.

FXIIa inhibitor rHA-Infestin-4: Safe thromboprotection in experimental venous, arterial and foreign surface-induced thrombosis.

May F, Krupka J, Fries M, Thielmann I, Pragst I, Weimer T, Panousis C, Nieswandt B, Stoll G, Dickneite G, Schulte S, Nolte MW.

Br J Haematol. 2016 Jun;173(5):769-78. doi: 10.1111/bjh.13990. Epub 2016 Mar 27.

PMID:
27018425
4.

The Coagulation Factor XIIa Inhibitor rHA-Infestin-4 Improves Outcome after Cerebral Ischemia/Reperfusion Injury in Rats.

Krupka J, May F, Weimer T, Pragst I, Kleinschnitz C, Stoll G, Panousis C, Dickneite G, Nolte MW.

PLoS One. 2016 Jan 27;11(1):e0146783. doi: 10.1371/journal.pone.0146783. eCollection 2016.

5.

Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage.

Herzog E, Kaspereit F, Krege W, Mueller-Cohrs J, Doerr B, Niebl P, Dickneite G.

J Thromb Haemost. 2015 Dec;13(12):2220-6. doi: 10.1111/jth.13165. Epub 2015 Nov 24.

6.

Utility of a high VWF: FVIII ratio in preventing FVIII accumulation: a study in VWF-deficient mice.

Raquet E, Stockschlaeder M, Mueller-Cohrs J, Zollner S, Pragst I, Dickneite G.

Blood Coagul Fibrinolysis. 2015 Jul;26(5):515-21. doi: 10.1097/MBC.0000000000000269.

7.

Coagulation factor XIII: a multifunctional transglutaminase with clinical potential in a range of conditions.

Dickneite G, Herwald H, Korte W, Allanore Y, Denton CP, Matucci Cerinic M.

Thromb Haemost. 2015 Apr;113(4):686-97. doi: 10.1160/TH14-07-0625. Epub 2015 Feb 5. Review.

PMID:
25652913
8.

Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding.

Herzog E, Kaspereit F, Krege W, Mueller-Cohrs J, Doerr B, Niebl P, Dickneite G.

Thromb Res. 2015 Mar;135(3):554-60. doi: 10.1016/j.thromres.2015.01.007. Epub 2015 Jan 9.

9.

Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage.

Herzog E, Kaspereit F, Krege W, Doerr B, Mueller-Cohrs J, Pragst I, Morishima Y, Dickneite G.

Anesthesiology. 2015 Feb;122(2):387-98. doi: 10.1097/ALN.0000000000000520.

PMID:
25419685
10.

Prothrombin complex concentrates as reversal agents for new oral anticoagulants: lessons from preclinical studies with Beriplex.

Dickneite G.

Clin Lab Med. 2014 Sep;34(3):623-35. doi: 10.1016/j.cll.2014.06.001. Epub 2014 Jul 18. Review.

PMID:
25168947
11.

C1-esterase inhibitor treatment: preclinical safety aspects on the potential prothrombotic risk.

Schürmann D, Herzog E, Raquet E, Nolte MW, May F, Müller-Cohrs J, Björkqvist J, Dickneite G, Pragst I.

Thromb Haemost. 2014 Nov;112(5):960-71. doi: 10.1160/TH13-06-0469. Epub 2014 Aug 7.

12.

Analysis of the safety and pharmacodynamics of human fibrinogen concentrate in animals.

Beyerle A, Nolte MW, Solomon C, Herzog E, Dickneite G.

Toxicol Appl Pharmacol. 2014 Oct 1;280(1):70-7. doi: 10.1016/j.taap.2014.07.019. Epub 2014 Aug 4.

13.

Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model.

Herzog E, Kaspereit FJ, Krege W, Doerr B, van Ryn J, Dickneite G, Pragst I.

Thromb Res. 2014 Sep;134(3):729-36. doi: 10.1016/j.thromres.2014.07.003. Epub 2014 Jul 11.

14.

Recombinant fusion protein linking factor VIIa with albumin (rVIIa-FP): Tissue distribution in rats.

Herzog E, Harris S, McEwen A, Henson C, Pragst I, Dickneite G, Schulte S, Zollner S.

Thromb Res. 2014 Aug;134(2):495-502. doi: 10.1016/j.thromres.2014.05.031. Epub 2014 May 29.

15.

Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII.

Zollner S, Raquet E, Claar P, Müller-Cohrs J, Metzner HJ, Weimer T, Pragst I, Dickneite G, Schulte S.

Thromb Res. 2014 Jul;134(1):125-31. doi: 10.1016/j.thromres.2014.03.028. Epub 2014 Mar 19.

16.

Biodistribution of the recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in rats.

Herzog E, Harris S, Henson C, McEwen A, Schenk S, Nolte MW, Pragst I, Dickneite G, Schulte S, Zollner S.

Thromb Res. 2014 May;133(5):900-7. doi: 10.1016/j.thromres.2014.02.010. Epub 2014 Feb 22.

17.

Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP).

Zollner S, Schuermann D, Raquet E, Mueller-Cohrs J, Weimer T, Pragst I, Dickneite G, Schulte S.

J Thromb Haemost. 2014 Feb;12(2):220-8. doi: 10.1111/jth.12477.

18.

A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk.

Larsson M, Rayzman V, Nolte MW, Nickel KF, Björkqvist J, Jämsä A, Hardy MP, Fries M, Schmidbauer S, Hedenqvist P, Broomé M, Pragst I, Dickneite G, Wilson MJ, Nash AD, Panousis C, Renné T.

Sci Transl Med. 2014 Feb 5;6(222):222ra17. doi: 10.1126/scitranslmed.3006804.

19.

Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?

Dickneite G, Hoffman M.

Thromb Haemost. 2014 Feb;111(2):189-98. doi: 10.1160/TH13-05-0431. Epub 2013 Oct 17. Review.

PMID:
24136202
20.

Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.

Zollner SB, Raquet E, Müller-Cohrs J, Metzner HJ, Weimer T, Pragst I, Dickneite G, Schulte S.

Thromb Res. 2013 Aug;132(2):280-7. doi: 10.1016/j.thromres.2013.06.017. Epub 2013 Jul 5.

21.

Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice.

Majmudar MD, Keliher EJ, Heidt T, Leuschner F, Truelove J, Sena BF, Gorbatov R, Iwamoto Y, Dutta P, Wojtkiewicz G, Courties G, Sebas M, Borodovsky A, Fitzgerald K, Nolte MW, Dickneite G, Chen JW, Anderson DG, Swirski FK, Weissleder R, Nahrendorf M.

Circulation. 2013 May 21;127(20):2038-46. doi: 10.1161/CIRCULATIONAHA.112.000116. Epub 2013 Apr 24.

22.

Selective factor XIIa inhibition attenuates silent brain ischemia: application of molecular imaging targeting coagulation pathway.

Chen JW, Figueiredo JL, Wojtkiewicz GR, Siegel C, Iwamoto Y, Kim DE, Nolte MW, Dickneite G, Weissleder R, Nahrendorf M.

JACC Cardiovasc Imaging. 2012 Nov;5(11):1127-38. doi: 10.1016/j.jcmg.2012.01.025.

23.

Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model.

Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G, van Ryn J.

J Thromb Haemost. 2012 Sep;10(9):1841-8. doi: 10.1111/j.1538-7836.2012.04859.x.

24.

C1-inhibitor protects from brain ischemia-reperfusion injury by combined antiinflammatory and antithrombotic mechanisms.

Heydenreich N, Nolte MW, Göb E, Langhauser F, Hofmeister M, Kraft P, Albert-Weissenberger C, Brede M, Varallyay C, Göbel K, Meuth SG, Nieswandt B, Dickneite G, Stoll G, Kleinschnitz C.

Stroke. 2012 Sep;43(9):2457-67. doi: 10.1161/STROKEAHA.112.660340. Epub 2012 Jun 28.

PMID:
22744646
25.

Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.

Nolte MW, Nichols TC, Mueller-Cohrs J, Merricks EP, Pragst I, Zollner S, Dickneite G.

J Thromb Haemost. 2012 Aug;10(8):1591-9. doi: 10.1111/j.1538-7836.2012.04826.x.

26.

Critical role of factor XIII in the initial stages of carbon tetrachloride-induced adult liver remodeling.

Tsujimoto I, Moriya K, Sakai K, Dickneite G, Sakai T.

Am J Pathol. 2011 Dec;179(6):3011-9. doi: 10.1016/j.ajpath.2011.08.037. Epub 2011 Oct 19.

27.

Repeated infusions of VWF/FVIII concentrate: impact of VWF:FVIII ratio on FVIII trough and peak levels in a rabbit model.

Raquet E, Stockschläder M, Dickneite G.

Haemophilia. 2011 Sep;17(5):808-14. doi: 10.1111/j.1365-2516.2011.02603.x. Epub 2011 Jul 4.

PMID:
21726357
28.

Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense.

Loof TG, Mörgelin M, Johansson L, Oehmcke S, Olin AI, Dickneite G, Norrby-Teglund A, Theopold U, Herwald H.

Blood. 2011 Sep 1;118(9):2589-98. doi: 10.1182/blood-2011-02-337568. Epub 2011 May 25.

PMID:
21613262
29.

Prothrombin complex concentrate mitigates diffuse bleeding after cardiopulmonary bypass in a porcine model.

Kaspereit F, Hoffmann S, Pragst I, Dickneite G.

Br J Anaesth. 2010 Nov;105(5):576-82. doi: 10.1093/bja/aeq216. Epub 2010 Aug 17.

30.

Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding.

Hagedorn I, Schmidbauer S, Pleines I, Kleinschnitz C, Kronthaler U, Stoll G, Dickneite G, Nieswandt B.

Circulation. 2010 Apr 6;121(13):1510-7. doi: 10.1161/CIRCULATIONAHA.109.924761. Epub 2010 Mar 22.

PMID:
20308613
31.

Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model.

Dickneite G, Dörr B, Kaspereit F, Tanaka KA.

J Trauma. 2010 May;68(5):1151-7. doi: 10.1097/TA.0b013e3181b06364.

PMID:
19996804
32.

Prothrombin complex concentrate (Beriplex P/N) for control of bleeding after kidney trauma in a rabbit dilutional coagulopathy model.

Pragst I, Kaspereit F, Dörr B, Dickneite G.

Thromb Res. 2010 Mar;125(3):272-7. doi: 10.1016/j.thromres.2009.10.011. Epub 2009 Nov 14.

PMID:
19913880
33.

Animal model and clinical evidence indicating low thrombogenic potential of fibrinogen concentrate (Haemocomplettan P).

Dickneite G, Pragst I, Joch C, Bergman GE.

Blood Coagul Fibrinolysis. 2009 Oct;20(7):535-40. doi: 10.1097/MBC.0b013e32832da1c5. Review.

PMID:
19710609
34.

Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model.

Dickneite G, Pragst I.

Br J Anaesth. 2009 Mar;102(3):345-54. doi: 10.1093/bja/aen391. Epub 2009 Jan 24.

35.
36.

Characterization of the coagulation deficit in porcine dilutional coagulopathy and substitution with a prothrombin complex concentrate.

Dickneite G, Doerr B, Kaspereit F.

Anesth Analg. 2008 Apr;106(4):1070-7, table of contents. doi: 10.1213/ane.0b013e318165dfbb.

PMID:
18349175
37.

Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation.

Tanaka KA, Szlam F, Dickneite G, Levy JH.

Thromb Res. 2008;122(1):117-23. Epub 2007 Oct 31.

PMID:
17977586
38.

Prevention of gynaecological adhesions using haemostatic fleece in a rabbit model.

Dickneite G, Rolle U, Rosenthal D.

J Int Med Res. 2006 Sep-Oct;34(5):505-13.

PMID:
17133779
39.
40.

Evaluation of the pro-angiogenic effect of factor XIII in heterotopic mouse heart allografts and FXIII-deficient mice.

Dardik R, Leor J, Skutelsky E, Castel D, Holbova R, Schiby G, Shaish A, Dickneite G, Loscalzo J, Inbal A.

Thromb Haemost. 2006 Mar;95(3):546-50.

PMID:
16525585
41.

Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction.

Nahrendorf M, Hu K, Frantz S, Jaffer FA, Tung CH, Hiller KH, Voll S, Nordbeck P, Sosnovik D, Gattenlöhner S, Novikov M, Dickneite G, Reed GL, Jakob P, Rosenzweig A, Bauer WR, Weissleder R, Ertl G.

Circulation. 2006 Mar 7;113(9):1196-202. Epub 2006 Feb 27.

42.

Role of FcRgamma and factor XIIIA in coated platelet formation.

Jobe SM, Leo L, Eastvold JS, Dickneite G, Ratliff TL, Lentz SR, Di Paola J.

Blood. 2005 Dec 15;106(13):4146-51. Epub 2005 Aug 16.

43.

Wound healing and degradation of the fibrin sealant Beriplast P following partial liver resection in rabbits.

Kroez M, Lang W, Dickneite G.

Wound Repair Regen. 2005 May-Jun;13(3):318-23.

PMID:
15953052
44.

The effect of fibrinogen concentrate administration on coagulation abnormalities in a rat sepsis model.

Kaspereit F, Doerr B, Dickneite G.

Blood Coagul Fibrinolysis. 2004 Jan;15(1):39-43.

PMID:
15166942
45.

A comparison of fibrin sealants in relation to their in vitro and in vivo properties.

Dickneite G, Metzner H, Pfeifer T, Kroez M, Witzke G.

Thromb Res. 2003;112(1-2):73-82.

PMID:
15013277
46.

Hypotension with intravenous immunoglobulin therapy: importance of pH and dimer formation.

Kroez M, Kanzy EJ, Gronski P, Dickneite G.

Biologicals. 2003 Dec;31(4):277-86.

PMID:
14624798
47.

Factor XIII A subunit-deficient mice developed severe uterine bleeding events and subsequent spontaneous miscarriages.

Koseki-Kuno S, Yamakawa M, Dickneite G, Ichinose A.

Blood. 2003 Dec 15;102(13):4410-2. Epub 2003 Aug 21.

PMID:
12933578
48.

Fibrin sealants in supporting surgical techniques: strength in factor XIII.

Phillips M, Dickneite G, Metzner H.

Cardiovasc Surg. 2003 Aug;11 Suppl 1:13-6. Review.

PMID:
12869983
49.

Targeted inactivation of the mouse locus encoding coagulation factor XIII-A: hemostatic abnormalities in mutant mice and characterization of the coagulation deficit.

Lauer P, Metzner HJ, Zettlmeissl G, Li M, Smith AG, Lathe R, Dickneite G.

Thromb Haemost. 2002 Dec;88(6):967-74.

PMID:
12529747
50.

The importance of factor XIII as a component of fibrin sealants.

Dickneite G, Metzner HJ, Kroez M, Hein B, Nicolay U.

J Surg Res. 2002 Oct;107(2):186-95.

PMID:
12429174

Supplemental Content

Loading ...
Support Center